Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen–Targeted 18F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide-Reference-Cited by-同舟云学术

Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen–Targeted 18F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide

Published:2021-02-19 Issue:10 Volume:62 Page:1430-1437
ISSN:0161-5505
Container-title:Journal of Nuclear Medicine
language:en
Short-container-title:J Nucl Med

Author:

Zukotynski Katherine A.,Emmenegger Urban,Hotte Sebastien,Kapoor Anil,Fu Wei,Blackford Amanda L.,Valliant John,Bénard François,Kim Chun K.,Markowski Mark C.,Eisenberger Mario A.,Antonarakis Emmanuel S.,Pienta Kenneth J.,Gorin Michael A.,Lubanovic Matthew,Kim Jihyun,Pomper Martin G.,Cho Steve Y.,Rowe Steven P.

Publisher

Society of Nuclear Medicine

Subject

Radiology, Nuclear Medicine and imaging

Reference19 articles.

1. Rowe SP Gorin MA Allaf ME . PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges. 2016;19:223–230.

2. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma

3. Prostate specific membrane antigen targeted 18F-DCFPyL positron emission tomography/computerized tomography for the preoperative staging of high risk prostate cancer: results of a prospective, phase II, single center study;Gorin;J Urol.,2018

4. Markowski MC Sedhom R Fu W . PSA and PSA doubling time predict findings on 18F-DCFPyL PET/CT in patients with biochemically-recurrent prostate cancer. J Urol. 2020;204:496–502.

5. [ 177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Correlation of [68Ga]Ga-PSMA PET/CT response and PSA decline in first-line enzalutamide for metastatic castration-resistant prostate cancer patients;European Journal of Nuclear Medicine and Molecular Imaging;2024-08-29

2. Prostate-specific Membrane Antigen;PET Clinics;2024-07

3. Prostate-Specific Membrane Antigen–Targeted Imaging and Its Correlation with HOXB13 Expression;Journal of Nuclear Medicine;2024-06-27

4. A prospective study on the early evaluation of response to androgen receptor-targeted agents with 11C-Choline, 68Ga-PSMA, and 18F-FACBC PET in metastatic castration-resistant prostate cancer: a single-center experience;ESMO Open;2024-05

5. PSMA-Targeted Radiopharmaceuticals for Prostate Cancer Diagnosis and Therapy;The Cancer Journal;2024-05